바로가기 메뉴
본문 바로가기
주메뉴 바로가기
김기향

Ki Hyang Kim

Hematology-oncology

Specialty

medical oncologoy

Treatment hours

Mon, Tue, Wed, Thur, Fri, Sat
Mon Tue Wed Thu Fri Sat
Education

2006.3-2008.2

Clinical fellow in Medical Oncology

Division of Medical Oncology, Department of Internal Medicine

In-Je University College of Medicine,Busan Paik Hospital,Busan, Korea

2010.3-2011.02

Clinical fellow in Medical Oncology,Division of Medical Oncology, Department of Internal Medicine,Yonsei Cancer Center, Yonsei University College of Medicine,Yonsei University Health System, Severance Hospital,Seoul, Korea

2011.03-2018.03 Assistant Professor,

Division of Medical Oncology, Department of Internal Medicine

In je University College of Medicine,

Busan Paik Hospital,Busan, Korea

2018.04-present Associate professor,

Division of Medical Oncology, Department of Internal Medicine

In je University College of Medicine,

Busan Paik Hospital,Busan, Korea

Career

2006.3-2008.2

Clinical fellow in Medical Oncology

Division of Medical Oncology, Department of Internal Medicine

In-Je University College of Medicine,Busan Paik Hospital,Busan, Korea

2010.3-2011.02

Clinical fellow in Medical Oncology,Division of Medical Oncology, Department of Internal Medicine,Yonsei Cancer Center, Yonsei University College of Medicine,Yonsei University Health System, Severance Hospital,Seoul, Korea

2011.03-2018.03 Assistant Professor,

Division of Medical Oncology, Department of Internal Medicine

In je University College of Medicine,

Busan Paik Hospital,Busan, Korea

2018.04-present Associate professor,

Division of Medical Oncology, Department of Internal Medicine

In je University College of Medicine,

Busan Paik Hospital,Busan, Korea

Main Activities

GI cancer,GU cancer,sarcoma,head and neck cancer,prostatic cancer

Research/Publication

.Korean J Intern Med. 2009 Mar;24(1):37-42.

Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin’s lymphoma.

Cancer Res Treat.2010 Dec;42(4):217-24

Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites

Cancer Res Treat. 2010 Sep;42(3):180-4

Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis

Oncology Letters 2012 Mar;3(3):699-703

Body fluid MMP-2 as a putative biomarker in metastatic breast cancer

Cancer Chemotherapy Pharmacology 2013 72:853-860

Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma

European Journal of Cancer 2014;50, 746-752

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency

BMC cancer 2014,14:647

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy

Oncology 2015;88:147-156

PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer